{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:52:09Z","timestamp":1790826729818,"version":"4.1.0"},"reference-count":15,"publisher":"Japan Atherosclerosis Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2023,1,1]]},"DOI":"10.5551\/jat.63348","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T22:07:35Z","timestamp":1645135655000},"page":"100-104","source":"Crossref","is-referenced-by-count":6,"title":["Anti-GPIHBP1 Antibody-Positive Autoimmune Hyperchylomicronemia and Immune Thrombocytopenia"],"prefix":"10.5551","volume":"30","author":[{"given":"Katsunao","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Koseki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Immuno-Biological Laboratories (IBL) Co., Ltd., Fujioka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Kanno","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayami","family":"Saga","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyang","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Omatsu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Inui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Ohama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishida","sequence":"additional","affiliation":[{"name":"Health Care Division, Health and Counseling Center, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Rinku General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Okazaki H, Gotoda T, Ogura M, Ishibashi S, Inagaki K, Daida H, Hayashi T, Hori M, Masuda D, Matsuki K, Yokoyama S and Harada-Shiba M: Current Diagnosis and Management of Primary Chylomicronemia. J Atheroscler Thromb, 2021; 28: 883-904","DOI":"10.5551\/jat.RV17054"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, Bujo H, Ishibashi S, Arai H, Yamashita S, Harada-Shiba M, Eto M, Hayashi T, Sone H, Suzuki H, Yamada N, Research Committee for Primary Hyperlipidemia RoMaIDbtMoHL and Welfare in J: Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb, 2012; 19: 1-12","DOI":"10.5551\/jat.10702"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kihara S, Matsuzawa Y, Kubo M, Nozaki S, Funahashi T, Yamashita S, Sho N and Tarui S: Autoimmune hyperchylomicronemia. N Engl J Med, 1989; 320: 1255-1259","DOI":"10.1056\/NEJM198905113201906"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Miyashita K, Fukamachi I, Machida T, Nakajima K, Young SG, Murakami M, Beigneux AP and Nakajima K: An ELISA for quantifying GPIHBP1 autoantibodies and making a diagnosis of the GPIHBP1 autoantibody syndrome. Clin Chim Acta, 2018; 487: 174-178","DOI":"10.1016\/j.cca.2018.09.039"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, Khovidhunkit W, Dufour R, Garg A, McMahon MA, Pullinger CR, Sandoval NP, Hu X, Allan CM, Larsson M, Machida T, Murakami M, Reue K, Tontonoz P, Goldberg IJ, Moulin P, Charriere S, Fong LG, Nakajima K and Young SG: Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia. N Engl J Med, 2017; 376: 1647-1658","DOI":"10.1056\/NEJMoa1611930"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Beigneux AP, Davies BS, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, Wong JS, Blaner WS, Ding ZM, Melford K, Wongsiriroj N, Shu X, de Sauvage F, Ryan RO, Fong LG, Bensadoun A and Young SG: Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab, 2007; 5: 279-291","DOI":"10.1016\/j.cmet.2007.02.002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Davies BS, Beigneux AP, Barnes RH, 2nd, Tu Y, Gin P, Weinstein MM, Nobumori C, Nyren R, Goldberg I, Olivecrona G, Bensadoun A, Young SG and Fong LG: GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab, 2010; 12: 42-52","DOI":"10.1016\/j.cmet.2010.04.016"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Hu X, Dallinga-Thie GM, Hovingh GK, Chang SY, Sandoval NP, Dang TLP, Fukamachi I, Miyashita K, Nakajima K, Murakami M, Fong LG, Ploug M, Young SG and Beigneux AP: GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia. J Clin Lipidol, 2017; 11: 964-971","DOI":"10.1016\/j.jacl.2017.05.017"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Eguchi J, Miyashita K, Fukamachi I, Nakajima K, Murakami M, Kawahara Y, Yamashita T, Ohta Y, Abe K, Nakatsuka A, Mino M, Takase S, Okazaki H, Hegele RA, Ploug M, Hu X, Wada J, Young SG and Beigneux AP: GPIHBP1 autoantibody syndrome during interferon beta1a treatment. J Clin Lipidol, 2019; 13: 62-69","DOI":"10.1016\/j.jacl.2018.10.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ashraf AP, Miyashita K, Nakajima K, Murakami M, Hegele RA, Ploug M, Fong LG, Young SG and Beigneux AP: Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies. J Clin Lipidol, 2020; 14: 197-200","DOI":"10.1016\/j.jacl.2020.01.012"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Imai M, Yamamoto H, Hashimoto T, Koyama H and Kihara S: Acquired marked hypertriglyceridemia with anti-GPIHBP1 antibodies. Pediatr Int, 2020; 62: 651-653","DOI":"10.1111\/ped.14154"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Lutz J, Dunaj-Kazmierowska M, Arcan S, Kassner U, Miyashita K, Murakami M, Ploug M, Fong LG, Young SG, Nakajima K and Beigneux AP: Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report. Ann Intern Med, 2020; 173: 764-765","DOI":"10.7326\/L20-0327"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yuka Hirano, Yasunori Suematsu, Yuiko Yano, Shuichi Sato, Shin-Ichiro Miura: A Woman With Hypertriglyceridemia Who Acquired Antibody Against GPIHBP1. JACC Case Rep, 2020; 2: 15-18","DOI":"10.1016\/j.jaccas.2019.11.052"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ida S, Kaneko R and Murata K: Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Cardiovasc Diabetol, 2019; 18: 38","DOI":"10.1186\/s12933-019-0845-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Iitake C, Masuda D, Koseki M and Yamashita S: Marked effects of novel selective peroxisome proliferator-activated receptor alpha modulator, pemafibrate in severe hypertriglyceridemia: preliminary report. Cardiovasc Diabetol, 2020; 19: 201","DOI":"10.1186\/s12933-020-01172-8"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/1\/30_63348\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T04:24:37Z","timestamp":1673065477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/1\/30_63348\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63348","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]},"article-number":"63348"}}